- Email: [email protected]
Clarithromycin against Mycobacterium avium complex infections
Tubercle and LungDisease (1996) 77, 19-26 © 1996 PearsonProfessionalLtd
Review article
Clarithromycin against Mycobacterium avium complex infections L. B. Heifets
National Jewish Center for Immunology and Respiratory Medicine and Department of Microbiology, University of Colorado Health Sciences Center S U M M A R Y. The turning point in antimicrobial therapy of Mycobacterium avium infections came with the development of two new macrolides, clarithromycin and azithromycin. Controlled clinical trials, the first ever conducted with any agent among patients with M. avium infection, indicated the high efficiency of clarithromycin, in either acquired immune deficiency syndrome (AIDS) patients having a disseminated infection or non-AIDS patients with localized p u l m o n a r y disease. M o n o t h e r a p y with clarithromycin resulted in elimination of bacteremia in almost all patients with disseminated infection, which is inevitably followed by a relapse of bacteremia in patients who survived long enough to reach this event. The strains susceptible to clarithromycin isolated before therapy contained l0 s or 10 -9 resistant mutants, and the relapses of bacteremia were caused by multiplication of these pre-existing mutants. Clarithromycin-resistance was associated with a mutation in the 23S r R N A gene. Cross-resistance between clarithromycin and azithromycin was confirmed with laboratory mutants and clinical isolates. At least two methods for determining the susceptibility of the M. avium isolates to clarithromycin are available: one is m i n i m u m inhibitory concentration (MIC) determination on Mueller-Hinton agar (pH 7.4) supplemented with 10% Oleic acid-albumin-dextrose catalase, the other is M I C determination in 7H12 broth, also at p H 7.4. The breakpoints for 'susceptible' for these methods are _<8.0 gg/ml and _<2.0 gg/ml, respectively. The breakpoints for 'resistant' are > 128 gg/ml for the agar method and > 32.0 ~tg/ml for the broth method. The predictability value of M I C determination was confirmed by comparing the test results with the patients' clinical and bacteriological response to therapy. The remaining m a j o r p r o b l e m in the therapy of the M. avium infections is a selection of companion drugs to be used in combination with clarithromycin (or azithromycin) to prevent the emergence of the macrolide-resistance. A n u m b e r of clinical trials are now in progress to find a solution to this problem. R/~ S U M/~. Le tournant dans le traitement antimicrobien des infections h Mycobacterium avium est survenu lors du d6veloppement de deux macrolides nouveaux, clarithromycine et azithromyeine. Des essais th6rapeutiques contr616s, les premiers A 6tre effectuds avec un agent ehez des malades atteints d ' u n e infection M. avium, ont indiqu6 l'effieacit6 sup6rieure de la darithromycine, soit chez des sid6ens porteurs d ' u n e infection diss6min6e, soit ehez des malades non-sid6ens atteints d ' u n e infection pulmonaire localisde. Une monoth6rapie p a r clarithromyeine a conduit $ l'61imination d ' u n e baet6ri6mie pour environ l'ensemble des malades avec infection diss6min6e, suivie presque in6vitablement d ' u n e rechute de bact6ri6mie chez les malades ayant surv6cu suffisamment longtemps p o u r atteindre ce stade. Les souches sensibles A la elarithromycine isol6es avant traitement eontenaient des mutants r6sistants de 10-8 ou 10 -9, et les rechutes de bact6ri6mie 6taient dues/i la multiplication de eeux-ci. Une r6sistance ~ la clarithromycine 6tait associ6e $ une mutation du g~ne 23S rRNA. Une r6sistance crois6e entre la clarithromycine et l'azithromyeine a 6t6 eonfirm6e en utilisant des mutants de laboratoire et des isolats cliniques. Au moins deux m6thodes de d6termination de la sensibilitd des isolats M. avium ~ la clarithromycine sont disponibles: l'une consiste en une d6termination de la C M I (concentration minimale inhibitriee), sur agar Mueller-Hinton (pH 7,4) suppldment6 p a r OADC ~ 10%, l ' a u t r e est une determination de la C M I sur bouillon 7H12, avec un p H de 7,4 6galement. Les points de s6paration p o u r la sensibilit6 de ees deux m6thodes sont respeetivement _<8,0 gg/ml et _<2,0 ~tg/ml. Les points de s6paration p o u r la r6sistance sont > 128 ktg/ml pour la m6thode utilisant l ' a g a r et 32,0 gg/ml pour la m6thode utilisant le bouillon. L a valeur pr6dictive de la ddtermination de la C M I a 6td confirm6e p a r une
Correspondenceto: L. B. HeifetsMD National Jewish Center, 1400 Jackson St, Denver, CO 80206, Tel: +303 398-1384; Fax: +303 3981953; Internet: [email protected]. 19
20 Tubercleand Lung Disease comparaison des r~sultats th~rapeutiques avec la r~ponse clinique et bact~riologique du malade au traitement. Le probl~me principal qui demeure dans le traitement des infections dues ~t M. avium est la s~lection des m~dicaments h utiliser en association avec la clarithromycine (ou l'azithromycine) afin de pr~venir l'~mergence d ' u n e r~sistance aux macrolides. N o m b r e d'essais th~rapeutiques sont actuellement en cours pour trouver une solution h ce probl~me. R E S U M E N. Un momento decisivo en el tratamiento antimicrobiano de las infecciones p o r Mycobacterium avium provino del desarrollo de 2 nuevos macr61idos, la claritromicina y la azitromicina. Varios estudios clinicos controlados, el p r i m e r o nunca antes realizado entre pacientes infeetados por M. avium, demostraron una gran eficacia de la claritromicina ya sea en pacientes de SIDA con una infecci6n diseminada o en pacientes sin SIDA con una enfermedad p u l m o n a r localizada. L a monoterapia con claritromicina result6 en la eliminaci6n de ia bacteremia en casi todos los pacientes con infecci6n diseminada, la cual es inevitablemente seguida de una recaida de la bacteremia en los pacientes que han sobrevivido lo suficiente como p a r a desarrollar este evento. Las cepas sensibles a la claritromieina aisladas antes del tratamiento contenian 10-s 6 10 -9 mutantes resistentes. Las recaldas de la bacteremia fueron provocadas por la multiplicaci6n de estos mutantes pre-existentes. L a resistencia a la claritromicina fue asociada a una mutaci6n en el gene A R N r 23S. La resistencia cruzada entre la claritromicina y la azitromicina fue confirmada con mutantes de laboratorio y con muestras clinicas. Se dispone de p o r 1o menos 2 m~todos p a r a determinar la sensibiUdad de M. avium a la claritromicina. Uno es la determinaci6n de la concentracion inhibidora minima (CIM) en un medio agar de Mueller-Hinton (pH 7,4) suplementado con OADC 10%, el otro es la determinaci6n de la C I M en el medio 7H12, tambi~n a un p H 7,4. Las C I M definitorias de "sensibilidad" de ambos m~todos son respectivamente ___8,0 gg/ml y _<2,0 gg/ml. Las C I M definitorias de "resistencia" son respectivamente > 128 gg/ml y > 32 gg/ml. El valor de predicci6n de la C I M rue confirmado c o m p a r a n d o los resultados del test con la respuesta clinica y bacteriol6gica de los pacientes tratados. Otro importante p r o b l e m a terap~utico de las infecciones por M. avium es la selecci6n de los medicamentos asociados a la administraci6n de claritromicina (o azitromicina) p a r a prevenir la emergencia de resistencia a los macr61idos. Un cierto n f m e r o de estudios clinieos est~in en curso p a r a obtener una respuesta a este problema.
INTRODUCTION Mycobacterium avium complex (MAC or MAI) includes M. avium and M. intracellulare and is the most frequent clinical isolate among more than 25 non-tuberculous mycobacterial species that can be found in human specimens. It is ubiquitous in the environment, 1-3 and the infections caused by these organisms are not transmissible from person to person. Before the acquired immune deficiency syndrome (AIDS) epidemic, the MAC infection most often manifested in humans was a localized pulmonary disease 3-7 which occurred in the USA in approximately 2000 patients annually. This contrasts sharply with the 24 000 to 39 000 patients with AIDS, who during 1991-1992 had disseminated MAC infection, a cumulative incidence of 15 to 24%, but the probability of this infection can be much higher in patients with CD4 lymphocyte counts less than 100 or 50 per ram3. 8-~2 The proportions of M. avium and M. intracellulare in patients with pulmonary disease reflect the distribution of these species in the environment of different geographic areas. 5'1~5 Most of the severe cases of pulmonary disease referred to the National Jewish Center in Denver were caused by M. intracellulare? 6 This 'selection' of patients who usually failed to respond to initial chemotherapy corresponds with the suggestion ~v that M. intracellulare is more resistant than M. avium to many of the conventional antituberculosis drugs. At the same time, isolates from AIDS patients with disseminated infection were almost exclusively M. avium. 18'19 These
differences between AIDS and non-AIDS patients should be taken into account when analyzing the effectiveness of treatment of the MAC infections in these two categories of patients. Antimicrobial therapy of pulmonary MAC disease often imitated drug regimens recommended for M. tuberculosis, for example isoniazid+streptomycin+ PZA, and usually resulted in failure. 2°,21 Retrospective analysis of treatment regimens that included rifampin and ethambutol have indicated s o m e s u c c e s s . 7'22-24 Diversity in views and uncertainty in selection of appropriate treatment regimens have been addressed in a number of reviews on the s u b j e c t . 7,1°,25-31 The turning point in antimicrobial therapy of MAC infections came with the introduction of clarithromycin and azithromycin and their evaluation in controlled clinical trials in patients with disseminated M. avium infection. The literature about clarithromycin, its general properties, pharmacology, and activity against other bacteria is extensive, and has been addressed in a number of reviews. 32-39 Therefore, this review has been limited to only one issue: the antimicrobial activity of this macrolide against MAC in various experimental conditions, with emphasis on correlation of these data with its efficacy in patients.
E F F I C A C Y IN P A T I E N T S The first clarithromycin clinical trial was conducted in 1988-1989 in France. 4° It was the first double-blind
Clafithromycinagainst MAC infections 21 placebo-controlled randomized trial ever performed in patients with M. avium infection. During the first 6 weeks of this pilot study (Phase I), eight patients received 1000 mg twice a day, while 7 patients received placebo. During the second 6 week period of observation (Phase II), the patients were crossed over: eight patients of the first group started receiving placebo, and only three patients of the second group started receiving clarithromycin. During this second period of observation, patients of both groups were administered four additional antituberculosis drugs (isoniazid, rifampin, ethambutol, clofazimine). The number of colony forming units (CFU)/ml in blood was increased in all patients receiving placebo during Phase I by a mean of 1.55 log~0, while the number of CFU/ml in those receiving clarithromycin decreased by a mean of 2.65 log~0, with complete eradication of bacteremia in seven of eight patients. During Phase II the relapse of bacteremia or increase of the number of CFU/ml was observed in four of eight patients after they were crossed over from clarithromycin to placebo, while a substantial decrease in the number of CFU/ml occurred in three patients treated during Phase II with clarithromycin. This shortterm trial provided the first clear evidence on the effectiveness of clarithromycin in the therapy of disseminated M. avium infection in patients with AIDS. It also demonstrated that the four-drug combination (isoniazid+ rifampin+ethambutol+clofazimine) was not effective. Similar results were obtained in another short-term randomized pilot trial in which four patients received clarithromycin and five patients were treated with isoniazid+ethambutol+ clofazimine. 41 These randomized pilot trials were followed by a prospective compassionateuse study to assess the long-term efficacy of clarithromycin in AIDS patients with disseminated M. avium infection. 42 Eradication of MAC bacteremia was achieved in 11 of 16 patients receiving 500 or 1000 mg/day and in 45 of 46 patients receiving 1500 or 2000 mg of clarithromycin along with various combinations of conventional antimycobacterial agents. A relapse of bacteremia occurred in 14 of 56 patients, and in 9 of 14 the isolates became resistant to clarithromycin. The results of the subsequent observations conducted in France 43 have shown that the initial eradication of bacteremia occurred in 93% of 173 AIDS patients treated with clarithromycin in combination with other drugs. The resistance associated with relapses of bacteremia was registered in 23% of 136 patients after 2 to 7 months of therapy. It is suggested that the only companion drug which appeared to protect against emerging resistance to clarithromycin was ethambutol, resulting in a twofold decrease in the relapse rate. 43 The first large-scale randomized, double-blind doseranging trial with clarithromycin was conducted in the USA in 1991-1992. 44 The 154 AIDS patients were divided into three groups (53, 51, and 50 patients) to receive 500 mg, 1000 mg, or 2000 mg twice daily for 12 weeks. Clarithomycin monotherapy was effective in more than 99% of patients, resulting in elimination of
the initial bacteremia, the symptoms associated with the MAC infection, and in a longer period of survival than could be expected for this type of patients. An average decline in the intensity of bacteremia was 2.7 log~0 of CFU/ml. Although the elimination of the initial bacteremia in patients receiving 500 mg occurred later than in the other two groups, the clinical and bacteriological response in general to this dose was the same or better than that seen in the other groups. The adverse reactions were highest among patients receiving 2000 mg (40%) compared to 16% and 15% in the other two groups. The proportion of patients who failed to complete 12-wk therapy was also the highest among patients receiving 2000 mg (58%) compared to 43% and 28% in groups treated with 1000 mg and 500 mg respectively. Based on these and other data, the dose 500 mg b.i.d. has been approved for therapy of disseminated M. avium infection in AIDS patients. Another macrolide, azithromycin, has also shown efficacy in the treatment of disseminated M. avium infection in AIDS patients. 4~ Although its reported ability to decrease the intensity of bacteremia was much lower than that of clarithromycin, an average of only 1.4 log10, the conclusion as to which of these two macrolides is more effective can be reached only in a controlled, randomized comparison trial. Either of these macrolides has been recommended as a mandatory element in the therapy of M. avium infection in AIDS patients, in combination with other agents. 46 Clarithromycin monotherapy also appeared to be effective in non-AIDS patients with localized pulmonary disease caused by either M. intraceIlulare or M. avium. In a non-randomized trial of 19 patients who had pretreatment isolates susceptible to clarithromycin and completed a minimum of 4 months monotherapy (500 mg b.i.d.), 11 converted to negative sputum culture and only two of them relapsed with the emergence of clarithromycin-resistance. 31 In addition, four other patients also had clearly favorable response to therapy with a substantial decline in the bacterial load in sputum. Besides these 15 patients with a definite response to therapy, two other patients were considered as indeterminant responders, and two were non-responders.
B A C T E R I O L O G I C A L RESPONSE TO T H E R A P Y AND THE ISSUE OF DRUG RESISTANCE Emergence of resistance of the MAC isolates to clarithromycin (minimum inhibitory concentration ([MIC] > 32 gg/ml) was registered in 46% of 152 patients, and was always associated with recrudescence of symptoms and relapse of bacteremia. 44 This rate does not reflect the actual probability of these events, since many patients discontinued therapy before the emergence of drug resistance could take place. Only 39 patients in this trial received 500 mg or 1000 mg for a period of 150 days or longer. One patient did not respond to therapy, and therefore only 38 patients were included in a detailed
22 Tubercleand Lung Disease analysis of the bacteriological response to the clarithromycin monotherapy. 47 The time required to achieve a negative culture or the lowest level of bacteremia depended on the intensity of the pretreatment bacteremia, ranging from 35.1 to 44.0 to 59.3 and 73.3 days for those whose CFUs per ml of blood were in a range < 100, 101-1000, 1001-10 000, and > 10 000, respectively. The average period of remission was 76.7 days, the longest of which (101.3 days) occurred among those with the lowest number of CFU/ml before treatment and shortest (42.7 days) among those with the largest number of CFU/ml before therapy. The relapse of bacteremia took place in all 38 patients after 116 to 136 days of treatment, and it has always been associated with the emergence of resistance to clarithromycin. It can be concluded from this analysis that the emergence of drug resistance is inevitable if the period of clarithromycin monotherapy is long enough for these events to take place. Multiple strains isolated during the period of decline of bacteremia were susceptible to 0.12 to 2.0 gg/ml, while those isolated during the relapse of bacteremia had an MIC of clarithromycin > 256.0 gg/ml when tested in 7H12 broth at pH 7.3-7.4. Direct susceptibility testing with blood specimens obtained during the relapse showed that up to 100% of the bacterial population consisted of these highly resistant bacteria, indicating that the susceptible population was eliminated during the initial phase of therapy. 47 Therefore, we concluded that the emergence of resistance was the result of multiplication of pre-existing resistant mutants, found with a frequency of 10 8 and 10 9 in M. avium strains susceptible to clarithromycin. The origin of the resistant strains isolated during the relapse of bacteremia was confirmed as being from the initial population by the restriction fragment length polymorphism testing of both in two laboratories. 48'49 These clarithromycin-resistant isolates were not different in their drug susceptibility/resistance pattern to the conventional antimycobacterial drugs, but showed clear cross-resistance to azithromycin. 47 Based on these data, it is speculated in this report that resistance to these macrolides may have a different mechanism than resistance of MAC to the conventional antimycobacterial drugs, which is usually associated with cell wall permeability. Resistance to clarithromycin in M. intracellulare has been identified as being associated with a mutation in the 23S rRNA position adenine 2 0 5 8 9 Resistance in M. avium isolated from the 38 patients was also found to be related to the mutation in the gene coding in 23S rRNA positions A2058/2059. 51
IN V I T R O SUSCEPTIBILITY TESTS The activity of clarithromycin against M. avium has been evaluated in a number of studies. 52-63 These publications, as well as a number of presentations at scientific meetings, have shown that the activity of clarithromycin in vitro depends on the type of medium (agar or broth) and pH conditions. The MICs in agar
media were four- to 16-fold greater than the brothd e t e r m i n e d M I C s . 58,s9 The MICs at pH 7.4 were two-to eight-fold lower than at pH 6.6-6.8 either in agar media 63 or in broth. 5s,62 The broth-determined MICs were 1.0 gg or less at pH 7.4, 1.0-4.0 at pH 6.8, and 8.0 and greater at pH 5.0 These data correspond with the fact that in general macrolides are more potent at a basic than at acidic pH against any organisms. 64,65Two types of media have been recommended for determining susceptibility to clarithromycin of the MAC clinical isolates: MuellerHinton pH 7.4 agar supplemented with 10% OADC and 7H12 broth adjusted to pH 7.4. 4°,44,58,63The results of the previously described large-scale randomized trial showed that all patients whose isolates were susceptible to 2.0 gg/ml or less when tested in 7H12 broth at pH 7.4 radiometrically (BACTEC) responded favorably to the treatment. 44,47 On the other hand, the MICs for all isolates obtained during the relapse of bacteremia were 256.0 gg/ml or greater, and these patients did not respond to continued therapy with clarithromycin. Therefore we have suggested 47 broth-determined MIC of 2.0 gg/ml as the breakpoint for 'susceptible,' which is the same as that established for most other bacterial species by the National Committee for Clinical Laboratory Standards. 66 The breakpoint for 'resistant' could be > 256.0 gg/ml, but for the convenience of testing we suggested classifying as resistant the MAC isolates with MIC > 32.0 gg/ml. Only two isolates obtained at the end of the decline of bacteremia from two of 154 patients had an MIC of 8.0 gg/ml; an MIC of 8.0 gg/ml was therefore suggested to classify such rare isolates as 'intermediate' or 'moderately susceptible'.47 The agar-determined MICs for strains susceptible to clarithromycin were not greater than 8.0 gg/ml, 5~ and this concentration can be suggested as a breakpoint for 'susceptible' using this method. To classify an isolate resistant to clarithromycin in the agar test, a concentration of > 128.0 gg/ml would be equivalent to > 32.0 gg/ml in broth. An intermediate concentration for the agar method would then be 32.0 gg/ml. These and other suggestions need to be evaluated for reproducibility of the results in a multi-laboratory study, which is currently in progress.
ACTIVITY AGAINST I N T R A C E L L U L A R BACTERIA It was shown that clarithromycin accumulates in polymorphonuclear leucocytes, in various tissues, and in macrophages. 67~° The intracellular/extracellular ratio was 9.2 and 16.7 in polymorphonuclear leucocytes. 67,68 The drug concentrations in infected macrophages exceeded the extracellular contents by 17-fold. 7° Quantitative assessment of the antimicrobial activity of clarithromycin has shown that for extracellular bacteria the MICs ranged from 0.25-1.0 and minimum bactericidal concentrations (MBCs) from 16.0-64.0 ~tg/ml; for intracellular bacteria the MICs were 0.5-1.0 ~tg/ml and MBCs 16.0 or 32.0 ~g/ml. 71 While some of the intracellular
Clarithromycin against MAC infections 23 bacteria may reside in phagosomes at neutral pH, a substantial proportion of the intracellular population may reside in phagolysosomes; 72 the activity of the drug in an acidic environment (pH 5.0) can be significantly diminished, with MICs of up to 16.0 gg/ml and greater. 58 The balance between the accumulation of the drug in macrophages and its diminished activity in acidic conditions resulted in the fact that complete inhibition of intracellular multiplication would require a minimum of 1.0 gg/ml to be present in extracellular fluid, which is the same as for extracellular bacteria at pH 7.4. Most of the other studies on the activity of clarithromycin against M. avium residing in macrophages have been performed with a drug concentration equivalent to the peak concentration in serum (Cma0, usually 4.0 gg/ml, to which the infected macrophages were exposed continuously for 7 days, 56,73-76 resulting in a decline in the number of bacteria in some of the observations. A 4week continuous exposure of infected macrophages to 2.0 gg/ml also resulted in a substantial decline in the number of viable bacteria. 77 Apparently such models do not reflect the in vivo events, since the exposure to Cm~` lasts for only a short period. The potential effect of Cm~ was evaluated by a 2 h pulsed exposure of the infected macrophages to 3.0 gg/ml, 78 producing complete inhibition of bacterial multiplication for 4 days, but no bactericidal effect was determined. Macrolide antibiotics are generally not considered bactericidal, and despite some suggestions about the bactericidal activity of clarithromycin 59,75'76 the overall assessment is that this agent produces only an inhibitory effect against M. avium at concentrations attainable in vivo. 34'58'60'73'79
MOUSE MODEL Clarithromycin has shown higher activity than any other agent tested against MAC infection in beige mice, resulting in a dramatic (up to 2 log10 or more) decrease in the number of bacteria in the lung, spleen, liver and bone marrow. 52,56,s°,81 This decline in the bacterial load has at times been classified as 'bactericidal' and at times as 'sterilizing.' The term 'sterilizing' is probably more appropriate for in vivo events, since it is not necessarily related to direct killing. The effectiveness of clarithromycin in beige mice was clearly dose-dependent, and dependent also on the duration of treatment, s°,s~ Besides the sterilizing activity, another similarity to the events that took place in patients was emergence of resistance to MAC after prolonged monotherapy. 82 These observations confirmed the validity of the beige mouse model for testing of the potential activity of antimicrobial agents against MAC infection.
'fall and rise phenomenon' described in the early years of monotherapy of tuberculosis with streptomycin or isoniazid, a3-86 These data led to the principle of multidrug therapy of tuberculosis with the initial purpose of preventing the emergence of drug resistance. It is very likely that the same approach will work in preventing clarithromycin resistance in patients with MAC infections. In searching for effective companion drugs, various combinations were tested in vitro, in macrophages, in mice and in limited clinical observations. Despite claims by some authors about a synergistic interaction between clarithromycin and other agents, the overall assessment of these interactions in vitro and in macrophages has shown only an additive effect. 59,75,77,sl's7-89 The beige mice models have been used to justify the use of amikacin in combination with other drugs. 9°-94 Comparison of the activity of various agents including clarithromycin in the beige mouse model has shown that amikacin was almost as active as clarithromycin, while rifampin and rifabutin were totally inactive, and ethambutol and sparfloxacin exhibited a limited inhibitory effect, s° The probability of emerging resistance to clarithromycin decreased when mice were treated with clarithromycin+ amikacin, but not with a combination of clarithromycin and minocycline. Observations in small groups of patients on the efficacy of various drugs that could be considered candidates for combination with clarithromycin have shown a broad diversity in results and interpretations 25'26'9°'95-99 Ethambutol reduced the intensity of MAC bacteremia in AIDS patients by only about 0.6 log~0 during one month of treatment, and a combination of this agent with clofazimine and rifampin resulted in a high rate of toxic side effects. 1°° In the same trial, rifampin monotherapy was not effective at all. The clinical efficacy of rifabutin has been evaluated in combination with other drugs, showing various percentages of patients with conversion to negative blood culture? t,95,1°l-j°4 A decrease in the intensity of bacteremia by 1.4-1.5 log~o or conversion to negative blood cultures was reported to occur in small groups of patients treated with a combination of rifampin+ethambutol+ciprofloxacin+amikacin, 9° or rifampin+ethambutol+ciprofloxacin+clofazimine. 105These mostly non-randomized trials have not provided clear conclusions as to the choices to be made, and now a number of controlled clinical trials to test the effect of various drug combinations with clarithromycin are in progress. As stated above, the relapse of bacteremia associated with emerging drug resistance occurred in all patients who were on clarithromycin monotherapy over a prolonged period. It can be suggested therefore that detection of a treatment regimen effectively preventing relapse of bacteremia will require a prolonged period of observation of not less than 4-5 months.
COMPANION DRUGS The events that took place in patients with disseminated M. avium infection treated with clarithromycin for a pro-
Acknowledgements
longed period of time have a striking similarity to the
Our studies summarizedin this review have been supported by grants
24
Tubercle and Lung Disease
from Abbott Laboratories (Abbott Park, IL). I thank P. Lindholm-Levy for editorial help and C. Queen for preparation of the manuscript.
References 1. Gruft H, Blanchard D, Wheeler J. Ocean waters a source of Mycobacterium intracellulare. Am Rev Respir Dis 1976; 113 (no. 4, part 2): 60. 2. Tsukamura M, Kita N, Shimoide H, Arakawa H, Kuze A. Studies on the epidemiology of nontuberculous mycobacteriosis in Japan. Am Rev Respir Dis 1988; 137: 1280-1284. 3. Tsukamura M, Shimoide H, Kita N e t al. Epidemiologic studies of lung disease due to mycobacteria other than Mycobacterium tuberculosis in Japan. Rev Infect Dis 1981; 3: 997-1007. 4. Wolinsky E. Nontuberculosis mycobacteria and associated diseases. Am Rev Respir Dis 1979; 119: 107-159. 5. Good R C, Snider Jr D E. Isolation of nontuberculous mycobacteria in the United States, 1980. J Infect Dis 1982; 146: 829. 6. Woods G L, Washington J A. Mycobacteria other than M. tuberculosis: a review of microbiologic and clinical aspects. Rev Inf Dis 1987; 9: 275-294. 7. Iseman M D, Corpe R F, O'Brien R J, Rosenzweig D Y, Wolinsky E. Disease due to Mycobacterium aviumintracellulare. Chest 1985; 87: 139S-145S. 8. Chaisson R E, Moore R D, Richman D D, Keruly J, Creagh T. Incidence mad natural history of Mycobacterium avium-complex infections in patients with advanced HIV disease treated with zidovudine. The Zidovudine Epidemiology Study Group. Am Rev Respir Dis 1992; 146: 285-289. 9. Hoover D R, Saah A J, Bacellar H, Phair J, Detels R, R. A. Clinical manifestations of AIDS in the era of Pneumocystis prophylaxis. N Engl J Med 1993; 329: 1922-1926. 10. Horsburgh Jr C R. Current concepts: Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med 1991; 324: 1332. 11. Horsburgh Jr C R, Selik R M. The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS). Am Rev Respir Dis 1989; 139: 4-7. 12. Nightingale S D, Byrd L T, Southern P M, Jockusch J D, Cal S X, Wynne B A. Incidence of Mycobacterium aviumintracellulare complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis 1992; 165: 1082-1085. 13. Falkinham III J O, Parker B C, Gruft H. Epidemiology of infection by nontuberculous mycobacteria. Am Rev Respir Dis 1980; 121: 931-937. 14. Parker B C, Ford M A, Graft H, Falkinham J O. Epidemiology of infection by nontuberculous mycobacteria. IV. Preferential aerosolization of M. intracellulare from natural waters. Am Rev Respir Dis 1983; 128: 652-656. 15. Wendt S G, George K L, Parker B C, Croft H, Falkinham J O. Epidemiology of infection by nontuberculous mycobacteria. III. Isolation of potentially pathogenic mycobacteria from aerosols. Am Rev Respir Dis 1980; 112: 259-263. 16. Heifets L, Iseman M D. Personal communication. 1993. 17. Tomioka H, Sato K, Saito H. In vitro susceptibilities of M. avium and M. intracellulare to various drugs. Kekkaku 1991; 66: 13-16. 18. Guthertz L S, Damsker B, E.J. B, Ford E G, Midura T F, Janda J M. M. avium and M. intracellulare infections in patients with and without AIDS. J Infect Dis 1989; 160: 1037-1041. 19. Yakrus M A, Good R C. Geographic distribution, frequency, mad specimen source of M. avium serotypes isolated from patients with acquired immunodeficiency syndrome. J Clin Microbiol 1990; 28: 926-931. 20. Bates J H. A study of pulmonary disease associated with mycobacteria other than Mycobacterium tuberculosis: clinical characteristics: XX. A report of the Veterans Administration - Armed Forces cooperative study on the chemotherapy of tuberculosis. Am Rev Respir Dis 1967; 96: 1151-1157. 21. Corpe R F. Clinical aspects, medical and surgical, in the management of Battey-type pulmonary disease. Chest 1964; 35: 380-382. 22. Davidson P T, Kanijo V, GoNe M, Moulding T S. Treatment of disease due to Mycobacterium intracellulare. Rev Infect Dis 1981; 3: 1052-1053.
23. Lester W, Fischer D A, Moulding T S, Fraser R I, McClatchy J K. 1968. Evaluation of chemotherapy responses in group III (Battey-type) mycobacterial infections, p. 20, Transaction of the 27th Veterans Administration - Armed Forces Pulmonary Disease Research Conference. 24. Lester W, Moulding T, Fraser R I, McClatchy J K. 1969. Quintuple drug regimens in the treatment of Battey-type infections, p. 83, Transactions of the 28th Veterans Administration - - Armed Forces Pulmonary Disease Research Conference. 25. Seydel J K, Schaper K J, Rtisch-Gerdes S. Development of effective drug combinations for the inhibition of multiply resistant mycobacteria, especially of the Mycobacterium avium complex. Chemotherapy 1992; 38: 159-168. 26. Hopewell P, Cynamon M, Starke J, Iseman M, O'Brien R. Evaluation of new anti-infective drugs for the treatment and prevention of infections caused by the Mycobacterium avium complex. Clin Inf Dis 1992; 15 (Suppl. 1): $296-$306. 27. Ellner J J, Goldberger M J, Parenti P M. Mycobacterium avium infection in AIDS: a therapeutic dilemma in rapid evolution. J Inf Dis 1993; 163: 1326-1335. 28. Heifets L B. Dilemmas and realities in drug susceptibility testing of M. avium-M, intracellulare and other slowly growing nontuberculous mycobacteria. In: Heifets L B. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press, 1991: 123-146. 29. Heifets L B, Iseman M D. Choice of antimicrobial agents for M. avium disease based on quantitative tests of drug susceptibility. N Engl J Med 1990; 323: 419-20. 30. Inderlied C B, Kemper C A, Bermudez L E M. The Mycobacterium avium complex. Clin Microbiol Rev 1993; 6: 266-310. 31. Wallace Jr R J, Brown B A, Griffith E et al. Initial clarithromycin monotherapy for Mycobacterium aviumintracellulare complex lung disease. Am J Respir Crit Care Med 1994; 149: 1335-1341. 32. Ferrero J L, Bopp B A, Marsh K C et al. Metabolism and disposition of clarithromycin in man. Drug Metabol Dispos 1990; 18: 441M46. 33. Finch R G, Speller D C E, Daly P J. Clarithromycin: new approaches to the treatment of respiratory tract infections. J Antimicrob Chemother 1991; 27 (Suppl. A): 1-124. 34. Baradell L B, Plosker G L, McTavish D. Clarithromycin. A review of its pharmacological properties and therapeutic use in Mycobacterium avium-intracellulare complex infection in patients with Acquired Immune Deficiency Syndrome. Drugs 1993; 46 (2): 289-312. 35. Piscitelli S C, Danziger L H, Rodvold K A. Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm 1992; 11: 137-152. 36. Surgill M G, Rapp R P. Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and andverse effects profiles. Ann Pharm 1992; 26: 1099-1108. 37. Kirst H A, Sides G D. New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy. Antimicrob, Agents Chemother 1989; 33: 1419-1422. 38. Chu S, Park Y, Locke C, Wilson D S, Cavanangh J C. Drugfood interaction potential of clarithromycin, a new macrolide antibiotic. J Clin Pharmacol 1992; 32: 32-36. 39. Nakayama I. Macrolides in clinical practice. In Omura Sed. Macrolide antibiotics: chemistry, biology and practice. Orlando, FL: Academic Press Inc., 1984: 261-300. 40. Dautzenberg B, Truffot C, Legris S e t al. Clarithromycin against Mycobacterium avium infection in AIDS patients: a controlled clinical trial. Am Rev Respir Dis 1991; 144: 564-569. 41. Ruf B, Schtirmann D, Mauch H, Jautzke G, Fehrenbach F J, Pohle H D. Effectiveness of the macrolide clarithromycin in the treatment of Mycobacterium avium complex infection in HIVinfected patients. Infection 1992; 20: 267-272. 42. Dantzenberg B, Saint Marc T, Meyohas M C et al. Clarithromycin and other antimycobacterial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immnnodeficiency syndrome. Arch Intern Med 1993; 153: 368-373. 43. Dautzenberg B. Clinical trials in M. avium therapy: lessons to take home. Res Microbiol 1994; 145: 197-206.
Clarithromycin against MAC infections 44. Chaisson R E, Benson C A, Dube M P e t al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. (A randomized, double-blind, dose-ranging study in patients with AIDS.) Ann Intern Med 1994; 121:905-911. 45. Young L S, Wiviott L, Wu M, Kolonoski P, Bolan R, Inderlied C B. Azithromycin for treatment of Mycobacterium aviumintracellulare complex infection in patients with AIDS. Lancet 1991; 338: 1107-1109. 46. Masur H, US Public Health Service Task Force on Prophylaxis and Therapy for M. avium complex. Recommendations on prophylaxis and therapy for disseminated M. avium complex disease in patients infected with the HIV (Special Report). N Engl J Med 1993; 329: 898-904. 47. Heifets L, Mor N, Vanderkolk J. 114.avium strains resistant to clarithromycin and azithromycin. Antimicrob Agents Chemother 1993; 37: 2364-2370. 48. Telenti A. Personal communication, i994. 49. Maznrek G H. Personal communication. 1993. 50. Meier A, Kirschner P, Springer Bet al. Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare. Antimicrob Agents Chemother 1994; 38: 381-384. 51. Meier A, Wallace R J, Sander P, Heifets L, BOttger E C. Molecular mechanisms of resistance to clarithromycin in mycobacteria. 95 ASM General Meeting 1995, Abstract U-41: 124. 52. Tomioka H, Sato K, Saito H. In vitro antimycobacterial activity of clarithromycin and its therapeutic efficacy against Mycobacterium intracellulare infection induced in mice. Kekkaku 1993; 68: 11-17. 53. Barry A L, Jones R N, Thornsberry C. In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin, Antimicrob Agents Chemother 1988; 32: 752-754. 54. Bahai N, Nahata M. The new macrolide antibiotics: azithromycin, clarithromycin, diritbromycin, and roxithromycin. Ann Pharmacother 1992; 25: 46-55. 55. Brown B A, Wallace Jr R J, Onyi G. Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system. Antimicrob Agents Chemother 1992; 36: 1987-1990. 56. Fernandes P B, Hardy D J, McDaniel D, Hanson C W, Swanson R N. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob Agents Chemother 1989; 33: 1531-1534. 57. Gorzynski E A, Gutman S I, Allen W. Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin. Antimicrob Agents Chemother 1989; 33: 591-592. 58. Heifets L B, Lindholm-Levy P J, Comstock R D. Clarithromycin minimal inhibitory and bactericidal concentrations. Am Rev Respir Dis 1992; 145: 856-858. 59. Kent R J, Bakhtiar M, Shanson D C. The in vitro bactericidal activities of combinations of antimicrobial agents against clinical isolates of Mycobacterium avium-intracellulare. J Antimicrob Chemother 1992; 30: 643-650. 60. Khardori N, Rolston K, Rosenbaum B, Hayat S, Bodey G P. Comparative in vitro activity of 20 antimicrobial agents against clinical isolates of Mycobacterium avium complex. J Antimicrob Chemother 1989, 24: 667-673. 61. Naik S, Ruck R. In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. Antimicrob Agents Chemother 1989; 33: 1614-1616. 62. Rastogi N, Gob K S. Effect of pH on radiometric MICs of clarithromycin against 18 species of mycobacteria. Antimicrob Agents Chemother 1992; 36: 2841-2842. 63. Truffot-Pernot C, Ji B, Grosset J. Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex. Antimicrob Agents Chemother 1991; 35: 1677-1678. 64. Hansen S L, Swomley P, Drusano G. Effect of carbon dioxide and pH on susceptibility of Bacteroidesfragilis group to erythromycin. Antimicrob Agents Chemother 1981; 19: 335-336. 65. Lorian V, Sabath L D. Effect of pH on the activity of erythromycin against 500 isolates of gram-negative bacilli. Appl Microbiol 1970; 20: 754-756.
25
66. National Committee for Clinical Laboratory Standards. 1992. Performance standards for antimicrobial susceptibility testing. In Jorgensen J H ed. National Committee for Clinical Laboratory Standards, M100-S4 ed, Villanova. 67. Anderson R, Joone G, van Rensburg C E J. An in vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent. J Antimicrob Chemother 1988; 22: 922-923. 68. Ishiguro M, Koga H, Kohno S, Hayashi T, Yamaguchi K, Hirota M. Penetration of macrolides into human polymolphonuclear leukocytes. J Antimicrob Chemother 1989; 24: 719-729. 69. Kohno Y, Yoshida H, Suwa T, Suga T. Uptake of clarithromycin by rat lung cells. J Antimicrob Chemother 1990; 26: 503-513. 70. Mor N, Vanderkolk J, Heifets L. Accumulation of clarithromycin in macrophages infected with M. avium. Pharmacotherapy 1994; 14 (1)(1): 100-104. 71. Mor N, Heifets L. MIC and MBC of clarithromycin against Mycobacterium avium within human macrophages. Antimicrob Agents Chemother 1993; 37:111-114. 72. deChastellier C, Frehel C, Offredo C, Skamene E. Implication of phagosome-lysosome fusion in restriction of M. avium growth in bone marrow macrophages from genetically resistant mice. Inf Immun 1993; 61: 3775-3784. 73. Perrone C, Gikas A, Truffot-Pernot C, Grosset J, Pocidalo J J, Vilde J L. Activities of clarithromycin sulfisoxale, and rifabutin against Mycobacterium avium complex multiplication within human macrophages. Antimicrob Agents Chemother 1990; 1508-1511. 74. Perrone C, Gikas A, Truffot-Pernot C, Grosset J, Vilde J L, Pocidalo J J. Activities of sparfloxacin, azithromycin, temafloxacin and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages. Antimicrob Agents Chemother 1991; 35: 1356-1359. 75. Rastogi N, Labrousse V. Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex. Antimocrob Agents Chemother 1991; 35: 462-470. 76. Yajko D M, Nassos P T, Sanders C A, Gonzalez P C, Hadley W K. Comparison of the intracellular activities of clarlithromycin and erythromycin against M. avium complex strains in J774 cells in alveolar macrophages from human immunodeficiency virus l-infected individuals. Antimicrob Agents Chemother 1992; 36: 1163-1165. 77. Mor N, Vanderkolk J, Mezo N, Heifets L. Effects of clarithromycin and rifabutin alone and in combination on intracellular and extracellutar replication of M. avium. Antimicrob Agents Chemother 1994; 38: 2738-2742. 78. Mor N, Heifers L. Inhibition of intracellular growth of M. avium by one pulsed exposure of infected macrophages to clarithromycin. Antimicrob Agents Chemother 1993; 37: 1380-1382. 79. Cohen Y, Perrone C, Truffot-Pernot C, Grosset J, Vilde J L. Activities of Win-57273, minocycline, clarithromycin, and 14-hydroxy-clarithromycin against Mycobacterium avium. Antimicrob Agents Chemother 1992; 36: 2104-2107. 80. Ji B, Lounis N, Truffot-Pernot C, Grosset J. Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model. Antimicrob Agents Chemother 1994; 38: 2521-2529. 81. Klemens S P, DeStefano M S, Cynamon M H. Activity of clarithromycin against Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother 1992; 36: 2413-2417. 82. Ji B, Lounis N, Truffot-Pernot C, Grosset J. Selection of resistant mutants of Mycobacterium avium in beige mice by clarithromycin monotherapy. Antimicrob Agents Chemother 1992; 36: 2839-2840. 83. Youmans G P, Williston E H, Feldman W, Hinshaw C H. Increase in resistance of tubercle bacilli to streptomycin. A preliminary report. Proc Mayo Clinic 1946; 21: 126-219. 84. Mitchison D A. Development of streptomycin resistant strains of tubercle bacilli in pulmonary tuberculosis. Thorax 1950; 4: 144-155.
26
Tubercle and Lung Disease
85. Medical Research Council. The treatment of pulmonary tuberculosis with isoniazid. Br Med J 1952; 2: 735-746. 86. Forbee S H, Theodore A, Mount F W. Long-term consequences of isoniazid alone as initial therapy: US PHS Tuberculosis Therapy Trials. Amer Rev Respir Dis 1960; 82: 824-830. 87. Heifets L B. Quantitative cultures and drug susceptibility testing of M. avium clinical isolates before and during the antimicrobial therapy. Res Microbiol 1994, 145: 188-196. 88. Heifets L B, Lindholm-Levy P J, Comstock R D. Bacteriostatic and bactericidal activities of gentamicin alone and in combination with clarithromycin against Mycobacterium avium. Anfimicrob Agents Chemother 1992; 36: 1695-1698. 89. Ji B, Lounis N, Truffot-Peruot C, Grosset J H. 1992. In vitro activities of clarithromycin-contalning double- or triple-drug combinations against Mycobacterium avium complex. Abstract 118. Program Abstract, First International Conference on Macrolides, Azalides and Streptomycins, vol. January, Santa Fe. 90. Chiu J, Nussbanm J, Bozzette S, Tilles J G, Young L S, Leedom J. Treatment of disseminated Mycobacterium avium complex infection with amikacin, ethambutol, rifampin, and ciprofloxacin. Ann Intern Med 1990; 113: 358-361. 91. Cynamon M H, Swenson C E, Palmer G S, Ginsberg R S. Liposome-encapsulated amikacin therapy of M. avium complex infection in beige mice. Antimicrob Agents Chemother 1989; 33: 1179-1183. 92. Gangadharam P R J, Perumal V K, Podapati N R, Kesavalu L, Iseman M D. In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother 1988; 32: 1400-1403. 93. Inderlied C B, Kolonoski P T, Wu M, Young L S. Amikacin; ciprofloxacin, and imipenem treatment for disseminated Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother 1989; 33: 176-180. 94. Saito H, Saito K. Activity of fifabufin alone and in combination with clofazimine, kanamycin and ethambutol against Mycobacterium intracellulare infections in mice. Tubercle 1989; 70: 201-205. 95. Agins B D, Berman D S, Spicehandler D, E1 Sadr W, Simberkoff M S, Rahal J J. Effect of combined therapy with ansamycin, clofazimine, ethambutol and isoniazid for Mycobacterium avium infection in patients with AIDS. J Infect Dis 1989; 159: 734-737.
96. Baron J E, Young L S. Amikacin, ethambutol, and rifampin for treatment of disseminated M. avium-intracellulare infection in patients with acquired immune deficiency syndrome. Diagn Microbiol Infect Dis 1986; 5: 215-220. 97. De Lalla F, Maserati R, Scarpellini P. Clarithromycinciprofloxacin-amikacin for therapy of Mycobacterium aviumMycobacterium intracellulare bacteremia in patients with AIDS. Antimicrob Agents Chemother 1992; 36: 1567-1569. 98. Benson C A, Kessler H A, Pottage Jr J C, Trenholme G M. Successful treatment of acquired immnnodeficiency syndromerelated Mycobacterium avium complex disease with a multiple drug regimen including amikacin. Arch Intern Med 1991; 151: 582-585. 99. Lazard T, Perronne C, Grosset J, Vilde J-L, Pocidalo J-J. Clarithromycin, minocycline, and rifabutin treatments before and after infection of C57BL/6 mice with M. avium. Antimicrob Agents Chemother 1993; 37: 1690-1692. 100. Kemper C A, Havlir D, Haghighat D, Dube M, Bartok A E, Sison J P. The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol and rifampin on Mycobacterium avium complex baeteremia in patients with AIDS. J Infect Dis 1994; 170: 157-164. 101. Hoy J, Mijch A, Sandlum M, Grayson L, Lucas R, Dwyer B. Quadruple-drug therapy for Mycobacterium avium intracellulare bacteremia in AIDS patients. J Infect Dis 1990; 161: 801-805. 102. Hawkins C C, Gold J W, Whimbey E et al. Mycobacterium avium complex infections in patients with acquired immunodeficiency syndrome. Ann Intern Med 1986; 105: 184-199. 103. Masnr H, Tuazon C, Gill V. Effect of combined clofazimine and ansamycin therapy of Mycobacterium aviumMycobacterium intracellulare bacteremia in patients with AIDS. J Infect Dis 1987; 155: 127-129. 104. Wong B, Edwards F F, Kiehn T E et al. Continuous high grade Mycobacterium avium intracellare bacteremia in patients with the acquired immune deficiency syndrome. Am J Med 1985; 78: 35-40. 105. Kemper C A, Meng T C, Nussbaum J, Chiu J, Fiegal D F, Bartok A E. Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug regimen: rifampin, ethmnbutol, clofazimine, and ciprofloxacin. Ann Intern Med 1992; 116: 466-472.
Review article
Clarithromycin against Mycobacterium avium complex infections L. B. Heifets
National Jewish Center for Immunology and Respiratory Medicine and Department of Microbiology, University of Colorado Health Sciences Center S U M M A R Y. The turning point in antimicrobial therapy of Mycobacterium avium infections came with the development of two new macrolides, clarithromycin and azithromycin. Controlled clinical trials, the first ever conducted with any agent among patients with M. avium infection, indicated the high efficiency of clarithromycin, in either acquired immune deficiency syndrome (AIDS) patients having a disseminated infection or non-AIDS patients with localized p u l m o n a r y disease. M o n o t h e r a p y with clarithromycin resulted in elimination of bacteremia in almost all patients with disseminated infection, which is inevitably followed by a relapse of bacteremia in patients who survived long enough to reach this event. The strains susceptible to clarithromycin isolated before therapy contained l0 s or 10 -9 resistant mutants, and the relapses of bacteremia were caused by multiplication of these pre-existing mutants. Clarithromycin-resistance was associated with a mutation in the 23S r R N A gene. Cross-resistance between clarithromycin and azithromycin was confirmed with laboratory mutants and clinical isolates. At least two methods for determining the susceptibility of the M. avium isolates to clarithromycin are available: one is m i n i m u m inhibitory concentration (MIC) determination on Mueller-Hinton agar (pH 7.4) supplemented with 10% Oleic acid-albumin-dextrose catalase, the other is M I C determination in 7H12 broth, also at p H 7.4. The breakpoints for 'susceptible' for these methods are _<8.0 gg/ml and _<2.0 gg/ml, respectively. The breakpoints for 'resistant' are > 128 gg/ml for the agar method and > 32.0 ~tg/ml for the broth method. The predictability value of M I C determination was confirmed by comparing the test results with the patients' clinical and bacteriological response to therapy. The remaining m a j o r p r o b l e m in the therapy of the M. avium infections is a selection of companion drugs to be used in combination with clarithromycin (or azithromycin) to prevent the emergence of the macrolide-resistance. A n u m b e r of clinical trials are now in progress to find a solution to this problem. R/~ S U M/~. Le tournant dans le traitement antimicrobien des infections h Mycobacterium avium est survenu lors du d6veloppement de deux macrolides nouveaux, clarithromycine et azithromyeine. Des essais th6rapeutiques contr616s, les premiers A 6tre effectuds avec un agent ehez des malades atteints d ' u n e infection M. avium, ont indiqu6 l'effieacit6 sup6rieure de la darithromycine, soit chez des sid6ens porteurs d ' u n e infection diss6min6e, soit ehez des malades non-sid6ens atteints d ' u n e infection pulmonaire localisde. Une monoth6rapie p a r clarithromyeine a conduit $ l'61imination d ' u n e baet6ri6mie pour environ l'ensemble des malades avec infection diss6min6e, suivie presque in6vitablement d ' u n e rechute de bact6ri6mie chez les malades ayant surv6cu suffisamment longtemps p o u r atteindre ce stade. Les souches sensibles A la elarithromycine isol6es avant traitement eontenaient des mutants r6sistants de 10-8 ou 10 -9, et les rechutes de bact6ri6mie 6taient dues/i la multiplication de eeux-ci. Une r6sistance ~ la clarithromycine 6tait associ6e $ une mutation du g~ne 23S rRNA. Une r6sistance crois6e entre la clarithromycine et l'azithromyeine a 6t6 eonfirm6e en utilisant des mutants de laboratoire et des isolats cliniques. Au moins deux m6thodes de d6termination de la sensibilitd des isolats M. avium ~ la clarithromycine sont disponibles: l'une consiste en une d6termination de la C M I (concentration minimale inhibitriee), sur agar Mueller-Hinton (pH 7,4) suppldment6 p a r OADC ~ 10%, l ' a u t r e est une determination de la C M I sur bouillon 7H12, avec un p H de 7,4 6galement. Les points de s6paration p o u r la sensibilit6 de ees deux m6thodes sont respeetivement _<8,0 gg/ml et _<2,0 ~tg/ml. Les points de s6paration p o u r la r6sistance sont > 128 ktg/ml pour la m6thode utilisant l ' a g a r et 32,0 gg/ml pour la m6thode utilisant le bouillon. L a valeur pr6dictive de la ddtermination de la C M I a 6td confirm6e p a r une
Correspondenceto: L. B. HeifetsMD National Jewish Center, 1400 Jackson St, Denver, CO 80206, Tel: +303 398-1384; Fax: +303 3981953; Internet: [email protected]. 19
20 Tubercleand Lung Disease comparaison des r~sultats th~rapeutiques avec la r~ponse clinique et bact~riologique du malade au traitement. Le probl~me principal qui demeure dans le traitement des infections dues ~t M. avium est la s~lection des m~dicaments h utiliser en association avec la clarithromycine (ou l'azithromycine) afin de pr~venir l'~mergence d ' u n e r~sistance aux macrolides. N o m b r e d'essais th~rapeutiques sont actuellement en cours pour trouver une solution h ce probl~me. R E S U M E N. Un momento decisivo en el tratamiento antimicrobiano de las infecciones p o r Mycobacterium avium provino del desarrollo de 2 nuevos macr61idos, la claritromicina y la azitromicina. Varios estudios clinicos controlados, el p r i m e r o nunca antes realizado entre pacientes infeetados por M. avium, demostraron una gran eficacia de la claritromicina ya sea en pacientes de SIDA con una infecci6n diseminada o en pacientes sin SIDA con una enfermedad p u l m o n a r localizada. L a monoterapia con claritromicina result6 en la eliminaci6n de ia bacteremia en casi todos los pacientes con infecci6n diseminada, la cual es inevitablemente seguida de una recaida de la bacteremia en los pacientes que han sobrevivido lo suficiente como p a r a desarrollar este evento. Las cepas sensibles a la claritromieina aisladas antes del tratamiento contenian 10-s 6 10 -9 mutantes resistentes. Las recaldas de la bacteremia fueron provocadas por la multiplicaci6n de estos mutantes pre-existentes. L a resistencia a la claritromicina fue asociada a una mutaci6n en el gene A R N r 23S. La resistencia cruzada entre la claritromicina y la azitromicina fue confirmada con mutantes de laboratorio y con muestras clinicas. Se dispone de p o r 1o menos 2 m~todos p a r a determinar la sensibiUdad de M. avium a la claritromicina. Uno es la determinaci6n de la concentracion inhibidora minima (CIM) en un medio agar de Mueller-Hinton (pH 7,4) suplementado con OADC 10%, el otro es la determinaci6n de la C I M en el medio 7H12, tambi~n a un p H 7,4. Las C I M definitorias de "sensibilidad" de ambos m~todos son respectivamente ___8,0 gg/ml y _<2,0 gg/ml. Las C I M definitorias de "resistencia" son respectivamente > 128 gg/ml y > 32 gg/ml. El valor de predicci6n de la C I M rue confirmado c o m p a r a n d o los resultados del test con la respuesta clinica y bacteriol6gica de los pacientes tratados. Otro importante p r o b l e m a terap~utico de las infecciones por M. avium es la selecci6n de los medicamentos asociados a la administraci6n de claritromicina (o azitromicina) p a r a prevenir la emergencia de resistencia a los macr61idos. Un cierto n f m e r o de estudios clinieos est~in en curso p a r a obtener una respuesta a este problema.
INTRODUCTION Mycobacterium avium complex (MAC or MAI) includes M. avium and M. intracellulare and is the most frequent clinical isolate among more than 25 non-tuberculous mycobacterial species that can be found in human specimens. It is ubiquitous in the environment, 1-3 and the infections caused by these organisms are not transmissible from person to person. Before the acquired immune deficiency syndrome (AIDS) epidemic, the MAC infection most often manifested in humans was a localized pulmonary disease 3-7 which occurred in the USA in approximately 2000 patients annually. This contrasts sharply with the 24 000 to 39 000 patients with AIDS, who during 1991-1992 had disseminated MAC infection, a cumulative incidence of 15 to 24%, but the probability of this infection can be much higher in patients with CD4 lymphocyte counts less than 100 or 50 per ram3. 8-~2 The proportions of M. avium and M. intracellulare in patients with pulmonary disease reflect the distribution of these species in the environment of different geographic areas. 5'1~5 Most of the severe cases of pulmonary disease referred to the National Jewish Center in Denver were caused by M. intracellulare? 6 This 'selection' of patients who usually failed to respond to initial chemotherapy corresponds with the suggestion ~v that M. intracellulare is more resistant than M. avium to many of the conventional antituberculosis drugs. At the same time, isolates from AIDS patients with disseminated infection were almost exclusively M. avium. 18'19 These
differences between AIDS and non-AIDS patients should be taken into account when analyzing the effectiveness of treatment of the MAC infections in these two categories of patients. Antimicrobial therapy of pulmonary MAC disease often imitated drug regimens recommended for M. tuberculosis, for example isoniazid+streptomycin+ PZA, and usually resulted in failure. 2°,21 Retrospective analysis of treatment regimens that included rifampin and ethambutol have indicated s o m e s u c c e s s . 7'22-24 Diversity in views and uncertainty in selection of appropriate treatment regimens have been addressed in a number of reviews on the s u b j e c t . 7,1°,25-31 The turning point in antimicrobial therapy of MAC infections came with the introduction of clarithromycin and azithromycin and their evaluation in controlled clinical trials in patients with disseminated M. avium infection. The literature about clarithromycin, its general properties, pharmacology, and activity against other bacteria is extensive, and has been addressed in a number of reviews. 32-39 Therefore, this review has been limited to only one issue: the antimicrobial activity of this macrolide against MAC in various experimental conditions, with emphasis on correlation of these data with its efficacy in patients.
E F F I C A C Y IN P A T I E N T S The first clarithromycin clinical trial was conducted in 1988-1989 in France. 4° It was the first double-blind
Clafithromycinagainst MAC infections 21 placebo-controlled randomized trial ever performed in patients with M. avium infection. During the first 6 weeks of this pilot study (Phase I), eight patients received 1000 mg twice a day, while 7 patients received placebo. During the second 6 week period of observation (Phase II), the patients were crossed over: eight patients of the first group started receiving placebo, and only three patients of the second group started receiving clarithromycin. During this second period of observation, patients of both groups were administered four additional antituberculosis drugs (isoniazid, rifampin, ethambutol, clofazimine). The number of colony forming units (CFU)/ml in blood was increased in all patients receiving placebo during Phase I by a mean of 1.55 log~0, while the number of CFU/ml in those receiving clarithromycin decreased by a mean of 2.65 log~0, with complete eradication of bacteremia in seven of eight patients. During Phase II the relapse of bacteremia or increase of the number of CFU/ml was observed in four of eight patients after they were crossed over from clarithromycin to placebo, while a substantial decrease in the number of CFU/ml occurred in three patients treated during Phase II with clarithromycin. This shortterm trial provided the first clear evidence on the effectiveness of clarithromycin in the therapy of disseminated M. avium infection in patients with AIDS. It also demonstrated that the four-drug combination (isoniazid+ rifampin+ethambutol+clofazimine) was not effective. Similar results were obtained in another short-term randomized pilot trial in which four patients received clarithromycin and five patients were treated with isoniazid+ethambutol+ clofazimine. 41 These randomized pilot trials were followed by a prospective compassionateuse study to assess the long-term efficacy of clarithromycin in AIDS patients with disseminated M. avium infection. 42 Eradication of MAC bacteremia was achieved in 11 of 16 patients receiving 500 or 1000 mg/day and in 45 of 46 patients receiving 1500 or 2000 mg of clarithromycin along with various combinations of conventional antimycobacterial agents. A relapse of bacteremia occurred in 14 of 56 patients, and in 9 of 14 the isolates became resistant to clarithromycin. The results of the subsequent observations conducted in France 43 have shown that the initial eradication of bacteremia occurred in 93% of 173 AIDS patients treated with clarithromycin in combination with other drugs. The resistance associated with relapses of bacteremia was registered in 23% of 136 patients after 2 to 7 months of therapy. It is suggested that the only companion drug which appeared to protect against emerging resistance to clarithromycin was ethambutol, resulting in a twofold decrease in the relapse rate. 43 The first large-scale randomized, double-blind doseranging trial with clarithromycin was conducted in the USA in 1991-1992. 44 The 154 AIDS patients were divided into three groups (53, 51, and 50 patients) to receive 500 mg, 1000 mg, or 2000 mg twice daily for 12 weeks. Clarithomycin monotherapy was effective in more than 99% of patients, resulting in elimination of
the initial bacteremia, the symptoms associated with the MAC infection, and in a longer period of survival than could be expected for this type of patients. An average decline in the intensity of bacteremia was 2.7 log~0 of CFU/ml. Although the elimination of the initial bacteremia in patients receiving 500 mg occurred later than in the other two groups, the clinical and bacteriological response in general to this dose was the same or better than that seen in the other groups. The adverse reactions were highest among patients receiving 2000 mg (40%) compared to 16% and 15% in the other two groups. The proportion of patients who failed to complete 12-wk therapy was also the highest among patients receiving 2000 mg (58%) compared to 43% and 28% in groups treated with 1000 mg and 500 mg respectively. Based on these and other data, the dose 500 mg b.i.d. has been approved for therapy of disseminated M. avium infection in AIDS patients. Another macrolide, azithromycin, has also shown efficacy in the treatment of disseminated M. avium infection in AIDS patients. 4~ Although its reported ability to decrease the intensity of bacteremia was much lower than that of clarithromycin, an average of only 1.4 log10, the conclusion as to which of these two macrolides is more effective can be reached only in a controlled, randomized comparison trial. Either of these macrolides has been recommended as a mandatory element in the therapy of M. avium infection in AIDS patients, in combination with other agents. 46 Clarithromycin monotherapy also appeared to be effective in non-AIDS patients with localized pulmonary disease caused by either M. intraceIlulare or M. avium. In a non-randomized trial of 19 patients who had pretreatment isolates susceptible to clarithromycin and completed a minimum of 4 months monotherapy (500 mg b.i.d.), 11 converted to negative sputum culture and only two of them relapsed with the emergence of clarithromycin-resistance. 31 In addition, four other patients also had clearly favorable response to therapy with a substantial decline in the bacterial load in sputum. Besides these 15 patients with a definite response to therapy, two other patients were considered as indeterminant responders, and two were non-responders.
B A C T E R I O L O G I C A L RESPONSE TO T H E R A P Y AND THE ISSUE OF DRUG RESISTANCE Emergence of resistance of the MAC isolates to clarithromycin (minimum inhibitory concentration ([MIC] > 32 gg/ml) was registered in 46% of 152 patients, and was always associated with recrudescence of symptoms and relapse of bacteremia. 44 This rate does not reflect the actual probability of these events, since many patients discontinued therapy before the emergence of drug resistance could take place. Only 39 patients in this trial received 500 mg or 1000 mg for a period of 150 days or longer. One patient did not respond to therapy, and therefore only 38 patients were included in a detailed
22 Tubercleand Lung Disease analysis of the bacteriological response to the clarithromycin monotherapy. 47 The time required to achieve a negative culture or the lowest level of bacteremia depended on the intensity of the pretreatment bacteremia, ranging from 35.1 to 44.0 to 59.3 and 73.3 days for those whose CFUs per ml of blood were in a range < 100, 101-1000, 1001-10 000, and > 10 000, respectively. The average period of remission was 76.7 days, the longest of which (101.3 days) occurred among those with the lowest number of CFU/ml before treatment and shortest (42.7 days) among those with the largest number of CFU/ml before therapy. The relapse of bacteremia took place in all 38 patients after 116 to 136 days of treatment, and it has always been associated with the emergence of resistance to clarithromycin. It can be concluded from this analysis that the emergence of drug resistance is inevitable if the period of clarithromycin monotherapy is long enough for these events to take place. Multiple strains isolated during the period of decline of bacteremia were susceptible to 0.12 to 2.0 gg/ml, while those isolated during the relapse of bacteremia had an MIC of clarithromycin > 256.0 gg/ml when tested in 7H12 broth at pH 7.3-7.4. Direct susceptibility testing with blood specimens obtained during the relapse showed that up to 100% of the bacterial population consisted of these highly resistant bacteria, indicating that the susceptible population was eliminated during the initial phase of therapy. 47 Therefore, we concluded that the emergence of resistance was the result of multiplication of pre-existing resistant mutants, found with a frequency of 10 8 and 10 9 in M. avium strains susceptible to clarithromycin. The origin of the resistant strains isolated during the relapse of bacteremia was confirmed as being from the initial population by the restriction fragment length polymorphism testing of both in two laboratories. 48'49 These clarithromycin-resistant isolates were not different in their drug susceptibility/resistance pattern to the conventional antimycobacterial drugs, but showed clear cross-resistance to azithromycin. 47 Based on these data, it is speculated in this report that resistance to these macrolides may have a different mechanism than resistance of MAC to the conventional antimycobacterial drugs, which is usually associated with cell wall permeability. Resistance to clarithromycin in M. intracellulare has been identified as being associated with a mutation in the 23S rRNA position adenine 2 0 5 8 9 Resistance in M. avium isolated from the 38 patients was also found to be related to the mutation in the gene coding in 23S rRNA positions A2058/2059. 51
IN V I T R O SUSCEPTIBILITY TESTS The activity of clarithromycin against M. avium has been evaluated in a number of studies. 52-63 These publications, as well as a number of presentations at scientific meetings, have shown that the activity of clarithromycin in vitro depends on the type of medium (agar or broth) and pH conditions. The MICs in agar
media were four- to 16-fold greater than the brothd e t e r m i n e d M I C s . 58,s9 The MICs at pH 7.4 were two-to eight-fold lower than at pH 6.6-6.8 either in agar media 63 or in broth. 5s,62 The broth-determined MICs were 1.0 gg or less at pH 7.4, 1.0-4.0 at pH 6.8, and 8.0 and greater at pH 5.0 These data correspond with the fact that in general macrolides are more potent at a basic than at acidic pH against any organisms. 64,65Two types of media have been recommended for determining susceptibility to clarithromycin of the MAC clinical isolates: MuellerHinton pH 7.4 agar supplemented with 10% OADC and 7H12 broth adjusted to pH 7.4. 4°,44,58,63The results of the previously described large-scale randomized trial showed that all patients whose isolates were susceptible to 2.0 gg/ml or less when tested in 7H12 broth at pH 7.4 radiometrically (BACTEC) responded favorably to the treatment. 44,47 On the other hand, the MICs for all isolates obtained during the relapse of bacteremia were 256.0 gg/ml or greater, and these patients did not respond to continued therapy with clarithromycin. Therefore we have suggested 47 broth-determined MIC of 2.0 gg/ml as the breakpoint for 'susceptible,' which is the same as that established for most other bacterial species by the National Committee for Clinical Laboratory Standards. 66 The breakpoint for 'resistant' could be > 256.0 gg/ml, but for the convenience of testing we suggested classifying as resistant the MAC isolates with MIC > 32.0 gg/ml. Only two isolates obtained at the end of the decline of bacteremia from two of 154 patients had an MIC of 8.0 gg/ml; an MIC of 8.0 gg/ml was therefore suggested to classify such rare isolates as 'intermediate' or 'moderately susceptible'.47 The agar-determined MICs for strains susceptible to clarithromycin were not greater than 8.0 gg/ml, 5~ and this concentration can be suggested as a breakpoint for 'susceptible' using this method. To classify an isolate resistant to clarithromycin in the agar test, a concentration of > 128.0 gg/ml would be equivalent to > 32.0 gg/ml in broth. An intermediate concentration for the agar method would then be 32.0 gg/ml. These and other suggestions need to be evaluated for reproducibility of the results in a multi-laboratory study, which is currently in progress.
ACTIVITY AGAINST I N T R A C E L L U L A R BACTERIA It was shown that clarithromycin accumulates in polymorphonuclear leucocytes, in various tissues, and in macrophages. 67~° The intracellular/extracellular ratio was 9.2 and 16.7 in polymorphonuclear leucocytes. 67,68 The drug concentrations in infected macrophages exceeded the extracellular contents by 17-fold. 7° Quantitative assessment of the antimicrobial activity of clarithromycin has shown that for extracellular bacteria the MICs ranged from 0.25-1.0 and minimum bactericidal concentrations (MBCs) from 16.0-64.0 ~tg/ml; for intracellular bacteria the MICs were 0.5-1.0 ~tg/ml and MBCs 16.0 or 32.0 ~g/ml. 71 While some of the intracellular
Clarithromycin against MAC infections 23 bacteria may reside in phagosomes at neutral pH, a substantial proportion of the intracellular population may reside in phagolysosomes; 72 the activity of the drug in an acidic environment (pH 5.0) can be significantly diminished, with MICs of up to 16.0 gg/ml and greater. 58 The balance between the accumulation of the drug in macrophages and its diminished activity in acidic conditions resulted in the fact that complete inhibition of intracellular multiplication would require a minimum of 1.0 gg/ml to be present in extracellular fluid, which is the same as for extracellular bacteria at pH 7.4. Most of the other studies on the activity of clarithromycin against M. avium residing in macrophages have been performed with a drug concentration equivalent to the peak concentration in serum (Cma0, usually 4.0 gg/ml, to which the infected macrophages were exposed continuously for 7 days, 56,73-76 resulting in a decline in the number of bacteria in some of the observations. A 4week continuous exposure of infected macrophages to 2.0 gg/ml also resulted in a substantial decline in the number of viable bacteria. 77 Apparently such models do not reflect the in vivo events, since the exposure to Cm~` lasts for only a short period. The potential effect of Cm~ was evaluated by a 2 h pulsed exposure of the infected macrophages to 3.0 gg/ml, 78 producing complete inhibition of bacterial multiplication for 4 days, but no bactericidal effect was determined. Macrolide antibiotics are generally not considered bactericidal, and despite some suggestions about the bactericidal activity of clarithromycin 59,75'76 the overall assessment is that this agent produces only an inhibitory effect against M. avium at concentrations attainable in vivo. 34'58'60'73'79
MOUSE MODEL Clarithromycin has shown higher activity than any other agent tested against MAC infection in beige mice, resulting in a dramatic (up to 2 log10 or more) decrease in the number of bacteria in the lung, spleen, liver and bone marrow. 52,56,s°,81 This decline in the bacterial load has at times been classified as 'bactericidal' and at times as 'sterilizing.' The term 'sterilizing' is probably more appropriate for in vivo events, since it is not necessarily related to direct killing. The effectiveness of clarithromycin in beige mice was clearly dose-dependent, and dependent also on the duration of treatment, s°,s~ Besides the sterilizing activity, another similarity to the events that took place in patients was emergence of resistance to MAC after prolonged monotherapy. 82 These observations confirmed the validity of the beige mouse model for testing of the potential activity of antimicrobial agents against MAC infection.
'fall and rise phenomenon' described in the early years of monotherapy of tuberculosis with streptomycin or isoniazid, a3-86 These data led to the principle of multidrug therapy of tuberculosis with the initial purpose of preventing the emergence of drug resistance. It is very likely that the same approach will work in preventing clarithromycin resistance in patients with MAC infections. In searching for effective companion drugs, various combinations were tested in vitro, in macrophages, in mice and in limited clinical observations. Despite claims by some authors about a synergistic interaction between clarithromycin and other agents, the overall assessment of these interactions in vitro and in macrophages has shown only an additive effect. 59,75,77,sl's7-89 The beige mice models have been used to justify the use of amikacin in combination with other drugs. 9°-94 Comparison of the activity of various agents including clarithromycin in the beige mouse model has shown that amikacin was almost as active as clarithromycin, while rifampin and rifabutin were totally inactive, and ethambutol and sparfloxacin exhibited a limited inhibitory effect, s° The probability of emerging resistance to clarithromycin decreased when mice were treated with clarithromycin+ amikacin, but not with a combination of clarithromycin and minocycline. Observations in small groups of patients on the efficacy of various drugs that could be considered candidates for combination with clarithromycin have shown a broad diversity in results and interpretations 25'26'9°'95-99 Ethambutol reduced the intensity of MAC bacteremia in AIDS patients by only about 0.6 log~0 during one month of treatment, and a combination of this agent with clofazimine and rifampin resulted in a high rate of toxic side effects. 1°° In the same trial, rifampin monotherapy was not effective at all. The clinical efficacy of rifabutin has been evaluated in combination with other drugs, showing various percentages of patients with conversion to negative blood culture? t,95,1°l-j°4 A decrease in the intensity of bacteremia by 1.4-1.5 log~o or conversion to negative blood cultures was reported to occur in small groups of patients treated with a combination of rifampin+ethambutol+ciprofloxacin+amikacin, 9° or rifampin+ethambutol+ciprofloxacin+clofazimine. 105These mostly non-randomized trials have not provided clear conclusions as to the choices to be made, and now a number of controlled clinical trials to test the effect of various drug combinations with clarithromycin are in progress. As stated above, the relapse of bacteremia associated with emerging drug resistance occurred in all patients who were on clarithromycin monotherapy over a prolonged period. It can be suggested therefore that detection of a treatment regimen effectively preventing relapse of bacteremia will require a prolonged period of observation of not less than 4-5 months.
COMPANION DRUGS The events that took place in patients with disseminated M. avium infection treated with clarithromycin for a pro-
Acknowledgements
longed period of time have a striking similarity to the
Our studies summarizedin this review have been supported by grants
24
Tubercle and Lung Disease
from Abbott Laboratories (Abbott Park, IL). I thank P. Lindholm-Levy for editorial help and C. Queen for preparation of the manuscript.
References 1. Gruft H, Blanchard D, Wheeler J. Ocean waters a source of Mycobacterium intracellulare. Am Rev Respir Dis 1976; 113 (no. 4, part 2): 60. 2. Tsukamura M, Kita N, Shimoide H, Arakawa H, Kuze A. Studies on the epidemiology of nontuberculous mycobacteriosis in Japan. Am Rev Respir Dis 1988; 137: 1280-1284. 3. Tsukamura M, Shimoide H, Kita N e t al. Epidemiologic studies of lung disease due to mycobacteria other than Mycobacterium tuberculosis in Japan. Rev Infect Dis 1981; 3: 997-1007. 4. Wolinsky E. Nontuberculosis mycobacteria and associated diseases. Am Rev Respir Dis 1979; 119: 107-159. 5. Good R C, Snider Jr D E. Isolation of nontuberculous mycobacteria in the United States, 1980. J Infect Dis 1982; 146: 829. 6. Woods G L, Washington J A. Mycobacteria other than M. tuberculosis: a review of microbiologic and clinical aspects. Rev Inf Dis 1987; 9: 275-294. 7. Iseman M D, Corpe R F, O'Brien R J, Rosenzweig D Y, Wolinsky E. Disease due to Mycobacterium aviumintracellulare. Chest 1985; 87: 139S-145S. 8. Chaisson R E, Moore R D, Richman D D, Keruly J, Creagh T. Incidence mad natural history of Mycobacterium avium-complex infections in patients with advanced HIV disease treated with zidovudine. The Zidovudine Epidemiology Study Group. Am Rev Respir Dis 1992; 146: 285-289. 9. Hoover D R, Saah A J, Bacellar H, Phair J, Detels R, R. A. Clinical manifestations of AIDS in the era of Pneumocystis prophylaxis. N Engl J Med 1993; 329: 1922-1926. 10. Horsburgh Jr C R. Current concepts: Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med 1991; 324: 1332. 11. Horsburgh Jr C R, Selik R M. The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS). Am Rev Respir Dis 1989; 139: 4-7. 12. Nightingale S D, Byrd L T, Southern P M, Jockusch J D, Cal S X, Wynne B A. Incidence of Mycobacterium aviumintracellulare complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis 1992; 165: 1082-1085. 13. Falkinham III J O, Parker B C, Gruft H. Epidemiology of infection by nontuberculous mycobacteria. Am Rev Respir Dis 1980; 121: 931-937. 14. Parker B C, Ford M A, Graft H, Falkinham J O. Epidemiology of infection by nontuberculous mycobacteria. IV. Preferential aerosolization of M. intracellulare from natural waters. Am Rev Respir Dis 1983; 128: 652-656. 15. Wendt S G, George K L, Parker B C, Croft H, Falkinham J O. Epidemiology of infection by nontuberculous mycobacteria. III. Isolation of potentially pathogenic mycobacteria from aerosols. Am Rev Respir Dis 1980; 112: 259-263. 16. Heifets L, Iseman M D. Personal communication. 1993. 17. Tomioka H, Sato K, Saito H. In vitro susceptibilities of M. avium and M. intracellulare to various drugs. Kekkaku 1991; 66: 13-16. 18. Guthertz L S, Damsker B, E.J. B, Ford E G, Midura T F, Janda J M. M. avium and M. intracellulare infections in patients with and without AIDS. J Infect Dis 1989; 160: 1037-1041. 19. Yakrus M A, Good R C. Geographic distribution, frequency, mad specimen source of M. avium serotypes isolated from patients with acquired immunodeficiency syndrome. J Clin Microbiol 1990; 28: 926-931. 20. Bates J H. A study of pulmonary disease associated with mycobacteria other than Mycobacterium tuberculosis: clinical characteristics: XX. A report of the Veterans Administration - Armed Forces cooperative study on the chemotherapy of tuberculosis. Am Rev Respir Dis 1967; 96: 1151-1157. 21. Corpe R F. Clinical aspects, medical and surgical, in the management of Battey-type pulmonary disease. Chest 1964; 35: 380-382. 22. Davidson P T, Kanijo V, GoNe M, Moulding T S. Treatment of disease due to Mycobacterium intracellulare. Rev Infect Dis 1981; 3: 1052-1053.
23. Lester W, Fischer D A, Moulding T S, Fraser R I, McClatchy J K. 1968. Evaluation of chemotherapy responses in group III (Battey-type) mycobacterial infections, p. 20, Transaction of the 27th Veterans Administration - Armed Forces Pulmonary Disease Research Conference. 24. Lester W, Moulding T, Fraser R I, McClatchy J K. 1969. Quintuple drug regimens in the treatment of Battey-type infections, p. 83, Transactions of the 28th Veterans Administration - - Armed Forces Pulmonary Disease Research Conference. 25. Seydel J K, Schaper K J, Rtisch-Gerdes S. Development of effective drug combinations for the inhibition of multiply resistant mycobacteria, especially of the Mycobacterium avium complex. Chemotherapy 1992; 38: 159-168. 26. Hopewell P, Cynamon M, Starke J, Iseman M, O'Brien R. Evaluation of new anti-infective drugs for the treatment and prevention of infections caused by the Mycobacterium avium complex. Clin Inf Dis 1992; 15 (Suppl. 1): $296-$306. 27. Ellner J J, Goldberger M J, Parenti P M. Mycobacterium avium infection in AIDS: a therapeutic dilemma in rapid evolution. J Inf Dis 1993; 163: 1326-1335. 28. Heifets L B. Dilemmas and realities in drug susceptibility testing of M. avium-M, intracellulare and other slowly growing nontuberculous mycobacteria. In: Heifets L B. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press, 1991: 123-146. 29. Heifets L B, Iseman M D. Choice of antimicrobial agents for M. avium disease based on quantitative tests of drug susceptibility. N Engl J Med 1990; 323: 419-20. 30. Inderlied C B, Kemper C A, Bermudez L E M. The Mycobacterium avium complex. Clin Microbiol Rev 1993; 6: 266-310. 31. Wallace Jr R J, Brown B A, Griffith E et al. Initial clarithromycin monotherapy for Mycobacterium aviumintracellulare complex lung disease. Am J Respir Crit Care Med 1994; 149: 1335-1341. 32. Ferrero J L, Bopp B A, Marsh K C et al. Metabolism and disposition of clarithromycin in man. Drug Metabol Dispos 1990; 18: 441M46. 33. Finch R G, Speller D C E, Daly P J. Clarithromycin: new approaches to the treatment of respiratory tract infections. J Antimicrob Chemother 1991; 27 (Suppl. A): 1-124. 34. Baradell L B, Plosker G L, McTavish D. Clarithromycin. A review of its pharmacological properties and therapeutic use in Mycobacterium avium-intracellulare complex infection in patients with Acquired Immune Deficiency Syndrome. Drugs 1993; 46 (2): 289-312. 35. Piscitelli S C, Danziger L H, Rodvold K A. Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm 1992; 11: 137-152. 36. Surgill M G, Rapp R P. Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and andverse effects profiles. Ann Pharm 1992; 26: 1099-1108. 37. Kirst H A, Sides G D. New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy. Antimicrob, Agents Chemother 1989; 33: 1419-1422. 38. Chu S, Park Y, Locke C, Wilson D S, Cavanangh J C. Drugfood interaction potential of clarithromycin, a new macrolide antibiotic. J Clin Pharmacol 1992; 32: 32-36. 39. Nakayama I. Macrolides in clinical practice. In Omura Sed. Macrolide antibiotics: chemistry, biology and practice. Orlando, FL: Academic Press Inc., 1984: 261-300. 40. Dautzenberg B, Truffot C, Legris S e t al. Clarithromycin against Mycobacterium avium infection in AIDS patients: a controlled clinical trial. Am Rev Respir Dis 1991; 144: 564-569. 41. Ruf B, Schtirmann D, Mauch H, Jautzke G, Fehrenbach F J, Pohle H D. Effectiveness of the macrolide clarithromycin in the treatment of Mycobacterium avium complex infection in HIVinfected patients. Infection 1992; 20: 267-272. 42. Dantzenberg B, Saint Marc T, Meyohas M C et al. Clarithromycin and other antimycobacterial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immnnodeficiency syndrome. Arch Intern Med 1993; 153: 368-373. 43. Dautzenberg B. Clinical trials in M. avium therapy: lessons to take home. Res Microbiol 1994; 145: 197-206.
Clarithromycin against MAC infections 44. Chaisson R E, Benson C A, Dube M P e t al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. (A randomized, double-blind, dose-ranging study in patients with AIDS.) Ann Intern Med 1994; 121:905-911. 45. Young L S, Wiviott L, Wu M, Kolonoski P, Bolan R, Inderlied C B. Azithromycin for treatment of Mycobacterium aviumintracellulare complex infection in patients with AIDS. Lancet 1991; 338: 1107-1109. 46. Masur H, US Public Health Service Task Force on Prophylaxis and Therapy for M. avium complex. Recommendations on prophylaxis and therapy for disseminated M. avium complex disease in patients infected with the HIV (Special Report). N Engl J Med 1993; 329: 898-904. 47. Heifets L, Mor N, Vanderkolk J. 114.avium strains resistant to clarithromycin and azithromycin. Antimicrob Agents Chemother 1993; 37: 2364-2370. 48. Telenti A. Personal communication, i994. 49. Maznrek G H. Personal communication. 1993. 50. Meier A, Kirschner P, Springer Bet al. Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare. Antimicrob Agents Chemother 1994; 38: 381-384. 51. Meier A, Wallace R J, Sander P, Heifets L, BOttger E C. Molecular mechanisms of resistance to clarithromycin in mycobacteria. 95 ASM General Meeting 1995, Abstract U-41: 124. 52. Tomioka H, Sato K, Saito H. In vitro antimycobacterial activity of clarithromycin and its therapeutic efficacy against Mycobacterium intracellulare infection induced in mice. Kekkaku 1993; 68: 11-17. 53. Barry A L, Jones R N, Thornsberry C. In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin, Antimicrob Agents Chemother 1988; 32: 752-754. 54. Bahai N, Nahata M. The new macrolide antibiotics: azithromycin, clarithromycin, diritbromycin, and roxithromycin. Ann Pharmacother 1992; 25: 46-55. 55. Brown B A, Wallace Jr R J, Onyi G. Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system. Antimicrob Agents Chemother 1992; 36: 1987-1990. 56. Fernandes P B, Hardy D J, McDaniel D, Hanson C W, Swanson R N. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob Agents Chemother 1989; 33: 1531-1534. 57. Gorzynski E A, Gutman S I, Allen W. Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin. Antimicrob Agents Chemother 1989; 33: 591-592. 58. Heifets L B, Lindholm-Levy P J, Comstock R D. Clarithromycin minimal inhibitory and bactericidal concentrations. Am Rev Respir Dis 1992; 145: 856-858. 59. Kent R J, Bakhtiar M, Shanson D C. The in vitro bactericidal activities of combinations of antimicrobial agents against clinical isolates of Mycobacterium avium-intracellulare. J Antimicrob Chemother 1992; 30: 643-650. 60. Khardori N, Rolston K, Rosenbaum B, Hayat S, Bodey G P. Comparative in vitro activity of 20 antimicrobial agents against clinical isolates of Mycobacterium avium complex. J Antimicrob Chemother 1989, 24: 667-673. 61. Naik S, Ruck R. In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. Antimicrob Agents Chemother 1989; 33: 1614-1616. 62. Rastogi N, Gob K S. Effect of pH on radiometric MICs of clarithromycin against 18 species of mycobacteria. Antimicrob Agents Chemother 1992; 36: 2841-2842. 63. Truffot-Pernot C, Ji B, Grosset J. Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex. Antimicrob Agents Chemother 1991; 35: 1677-1678. 64. Hansen S L, Swomley P, Drusano G. Effect of carbon dioxide and pH on susceptibility of Bacteroidesfragilis group to erythromycin. Antimicrob Agents Chemother 1981; 19: 335-336. 65. Lorian V, Sabath L D. Effect of pH on the activity of erythromycin against 500 isolates of gram-negative bacilli. Appl Microbiol 1970; 20: 754-756.
25
66. National Committee for Clinical Laboratory Standards. 1992. Performance standards for antimicrobial susceptibility testing. In Jorgensen J H ed. National Committee for Clinical Laboratory Standards, M100-S4 ed, Villanova. 67. Anderson R, Joone G, van Rensburg C E J. An in vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent. J Antimicrob Chemother 1988; 22: 922-923. 68. Ishiguro M, Koga H, Kohno S, Hayashi T, Yamaguchi K, Hirota M. Penetration of macrolides into human polymolphonuclear leukocytes. J Antimicrob Chemother 1989; 24: 719-729. 69. Kohno Y, Yoshida H, Suwa T, Suga T. Uptake of clarithromycin by rat lung cells. J Antimicrob Chemother 1990; 26: 503-513. 70. Mor N, Vanderkolk J, Heifets L. Accumulation of clarithromycin in macrophages infected with M. avium. Pharmacotherapy 1994; 14 (1)(1): 100-104. 71. Mor N, Heifets L. MIC and MBC of clarithromycin against Mycobacterium avium within human macrophages. Antimicrob Agents Chemother 1993; 37:111-114. 72. deChastellier C, Frehel C, Offredo C, Skamene E. Implication of phagosome-lysosome fusion in restriction of M. avium growth in bone marrow macrophages from genetically resistant mice. Inf Immun 1993; 61: 3775-3784. 73. Perrone C, Gikas A, Truffot-Pernot C, Grosset J, Pocidalo J J, Vilde J L. Activities of clarithromycin sulfisoxale, and rifabutin against Mycobacterium avium complex multiplication within human macrophages. Antimicrob Agents Chemother 1990; 1508-1511. 74. Perrone C, Gikas A, Truffot-Pernot C, Grosset J, Vilde J L, Pocidalo J J. Activities of sparfloxacin, azithromycin, temafloxacin and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages. Antimicrob Agents Chemother 1991; 35: 1356-1359. 75. Rastogi N, Labrousse V. Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex. Antimocrob Agents Chemother 1991; 35: 462-470. 76. Yajko D M, Nassos P T, Sanders C A, Gonzalez P C, Hadley W K. Comparison of the intracellular activities of clarlithromycin and erythromycin against M. avium complex strains in J774 cells in alveolar macrophages from human immunodeficiency virus l-infected individuals. Antimicrob Agents Chemother 1992; 36: 1163-1165. 77. Mor N, Vanderkolk J, Mezo N, Heifets L. Effects of clarithromycin and rifabutin alone and in combination on intracellular and extracellutar replication of M. avium. Antimicrob Agents Chemother 1994; 38: 2738-2742. 78. Mor N, Heifers L. Inhibition of intracellular growth of M. avium by one pulsed exposure of infected macrophages to clarithromycin. Antimicrob Agents Chemother 1993; 37: 1380-1382. 79. Cohen Y, Perrone C, Truffot-Pernot C, Grosset J, Vilde J L. Activities of Win-57273, minocycline, clarithromycin, and 14-hydroxy-clarithromycin against Mycobacterium avium. Antimicrob Agents Chemother 1992; 36: 2104-2107. 80. Ji B, Lounis N, Truffot-Pernot C, Grosset J. Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model. Antimicrob Agents Chemother 1994; 38: 2521-2529. 81. Klemens S P, DeStefano M S, Cynamon M H. Activity of clarithromycin against Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother 1992; 36: 2413-2417. 82. Ji B, Lounis N, Truffot-Pernot C, Grosset J. Selection of resistant mutants of Mycobacterium avium in beige mice by clarithromycin monotherapy. Antimicrob Agents Chemother 1992; 36: 2839-2840. 83. Youmans G P, Williston E H, Feldman W, Hinshaw C H. Increase in resistance of tubercle bacilli to streptomycin. A preliminary report. Proc Mayo Clinic 1946; 21: 126-219. 84. Mitchison D A. Development of streptomycin resistant strains of tubercle bacilli in pulmonary tuberculosis. Thorax 1950; 4: 144-155.
26
Tubercle and Lung Disease
85. Medical Research Council. The treatment of pulmonary tuberculosis with isoniazid. Br Med J 1952; 2: 735-746. 86. Forbee S H, Theodore A, Mount F W. Long-term consequences of isoniazid alone as initial therapy: US PHS Tuberculosis Therapy Trials. Amer Rev Respir Dis 1960; 82: 824-830. 87. Heifets L B. Quantitative cultures and drug susceptibility testing of M. avium clinical isolates before and during the antimicrobial therapy. Res Microbiol 1994, 145: 188-196. 88. Heifets L B, Lindholm-Levy P J, Comstock R D. Bacteriostatic and bactericidal activities of gentamicin alone and in combination with clarithromycin against Mycobacterium avium. Anfimicrob Agents Chemother 1992; 36: 1695-1698. 89. Ji B, Lounis N, Truffot-Peruot C, Grosset J H. 1992. In vitro activities of clarithromycin-contalning double- or triple-drug combinations against Mycobacterium avium complex. Abstract 118. Program Abstract, First International Conference on Macrolides, Azalides and Streptomycins, vol. January, Santa Fe. 90. Chiu J, Nussbanm J, Bozzette S, Tilles J G, Young L S, Leedom J. Treatment of disseminated Mycobacterium avium complex infection with amikacin, ethambutol, rifampin, and ciprofloxacin. Ann Intern Med 1990; 113: 358-361. 91. Cynamon M H, Swenson C E, Palmer G S, Ginsberg R S. Liposome-encapsulated amikacin therapy of M. avium complex infection in beige mice. Antimicrob Agents Chemother 1989; 33: 1179-1183. 92. Gangadharam P R J, Perumal V K, Podapati N R, Kesavalu L, Iseman M D. In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother 1988; 32: 1400-1403. 93. Inderlied C B, Kolonoski P T, Wu M, Young L S. Amikacin; ciprofloxacin, and imipenem treatment for disseminated Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother 1989; 33: 176-180. 94. Saito H, Saito K. Activity of fifabufin alone and in combination with clofazimine, kanamycin and ethambutol against Mycobacterium intracellulare infections in mice. Tubercle 1989; 70: 201-205. 95. Agins B D, Berman D S, Spicehandler D, E1 Sadr W, Simberkoff M S, Rahal J J. Effect of combined therapy with ansamycin, clofazimine, ethambutol and isoniazid for Mycobacterium avium infection in patients with AIDS. J Infect Dis 1989; 159: 734-737.
96. Baron J E, Young L S. Amikacin, ethambutol, and rifampin for treatment of disseminated M. avium-intracellulare infection in patients with acquired immune deficiency syndrome. Diagn Microbiol Infect Dis 1986; 5: 215-220. 97. De Lalla F, Maserati R, Scarpellini P. Clarithromycinciprofloxacin-amikacin for therapy of Mycobacterium aviumMycobacterium intracellulare bacteremia in patients with AIDS. Antimicrob Agents Chemother 1992; 36: 1567-1569. 98. Benson C A, Kessler H A, Pottage Jr J C, Trenholme G M. Successful treatment of acquired immnnodeficiency syndromerelated Mycobacterium avium complex disease with a multiple drug regimen including amikacin. Arch Intern Med 1991; 151: 582-585. 99. Lazard T, Perronne C, Grosset J, Vilde J-L, Pocidalo J-J. Clarithromycin, minocycline, and rifabutin treatments before and after infection of C57BL/6 mice with M. avium. Antimicrob Agents Chemother 1993; 37: 1690-1692. 100. Kemper C A, Havlir D, Haghighat D, Dube M, Bartok A E, Sison J P. The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol and rifampin on Mycobacterium avium complex baeteremia in patients with AIDS. J Infect Dis 1994; 170: 157-164. 101. Hoy J, Mijch A, Sandlum M, Grayson L, Lucas R, Dwyer B. Quadruple-drug therapy for Mycobacterium avium intracellulare bacteremia in AIDS patients. J Infect Dis 1990; 161: 801-805. 102. Hawkins C C, Gold J W, Whimbey E et al. Mycobacterium avium complex infections in patients with acquired immunodeficiency syndrome. Ann Intern Med 1986; 105: 184-199. 103. Masnr H, Tuazon C, Gill V. Effect of combined clofazimine and ansamycin therapy of Mycobacterium aviumMycobacterium intracellulare bacteremia in patients with AIDS. J Infect Dis 1987; 155: 127-129. 104. Wong B, Edwards F F, Kiehn T E et al. Continuous high grade Mycobacterium avium intracellare bacteremia in patients with the acquired immune deficiency syndrome. Am J Med 1985; 78: 35-40. 105. Kemper C A, Meng T C, Nussbaum J, Chiu J, Fiegal D F, Bartok A E. Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug regimen: rifampin, ethmnbutol, clofazimine, and ciprofloxacin. Ann Intern Med 1992; 116: 466-472.